There are 2789 resources available
250P - Palbociclib: Early treatment-related neutropenia as a potential pharmacodynamic marker?
Presenter: Xenia Fernandez Sala
Session: ePoster Display
252P - Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?
Presenter: Claudia Noto
Session: ePoster Display
1430P - Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
Presenter: Christina Kopp
Session: ePoster Display
1431P - Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital
Presenter: Oriol Mirallas
Session: ePoster Display
1432P - Characterizing diversity in the immune profile by a transcriptomic customized gene signature to potentially personalize treatment in advanced gastric cancer patients
Presenter: Manuel Cabeza-Segura
Session: ePoster Display
1433P - Esophageal cancer cell dynamics significantly depended on blood cell circuit, biochemical factors, hemostasis system, cancer characteristics and anthropometric data
Presenter: Oleg Kshivets
Session: ePoster Display
1434TiP - MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
Presenter: Daniel Catenacci
Session: ePoster Display
1435TiP - Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial
Presenter: Xiaozheng Kang
Session: ePoster Display
1436TiP - Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
Presenter: Kohei Shitara
Session: ePoster Display